KRAS and pancreatic neoplasm: It can also inhibit the growth of KRAS mutated colorectal and pancreatic cancer in combination with cetuximab (Rosa et al. 2011; Damiano et al. 2006; Damiano et al. 2007; Damiano et al. 2009; Basith et al. 2012).